Therapeutic targeting of VEGF in the treatment of glioblastoma

Bibliography

• Kohler BA, Ward E, McCarthy BJ, Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011;103(9):714-36
   PubMedGoogle Scholar
• CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 (March 23, 2012 Revision) Central Brain Tumor Registry of the United States, Hinsdale, IL. 2012. Available from: www.cbtrus.org
   Google Scholar
• Phillips HS, Kharbanda S, Chen R, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3):157-73
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98-110
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972;48(2):347-56
   PubMed Web of Science ®Google Scholar
• Kleihues P, Louis DN, Scheithauer BW, The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61(3):215-25; discussion 26-9
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6
   PubMed Web of Science ®Google Scholar
• Baluk P, Morikawa S, Haskell A, Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003;163(5):1801-15
   PubMed Web of Science ®Google Scholar
• Vitolo D, Paradiso P, Uccini S, Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology 1996;28(6):521-8
   Google Scholar
• Jain RK, di Tomaso E, Duda DG, Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8(8):610-22
   PubMed Web of Science ®Google Scholar
• Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993;268(29):21513-18
   PubMed Web of Science ®Google Scholar
• Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000;19(16):4298-309
   PubMed Web of Science ®Google Scholar
• Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272(36):22642-7
   PubMed Web of Science ®Google Scholar
• Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64(5-6):993-8
   PubMed Web of Science ®Google Scholar
• Kelly BD, Hackett SF, Hirota K, Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003;93(11):1074-81
   PubMed Web of Science ®Google Scholar
• Krishnamachary B, Berg-Dixon S, Kelly B, Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003;63(5):1138-43
   PubMed Web of Science ®Google Scholar
• Kaur B, Khwaja FW, Severson EA, Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005;7(2):134-53
   PubMed Web of Science ®Google Scholar
• Fischer I, Gagner JP, Law M, Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005;15(4):297-310
   PubMed Web of Science ®Google Scholar
• Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J Neurooncol 2006;78(3):281-93
   PubMed Web of Science ®Google Scholar
• Rahman R, Smith S, Rahman C, Grundy R. Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol 2010;2010:251231
   PubMedGoogle Scholar
• Nagy JA, Benjamin L, Zeng H, Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008;11(2):109-19
   PubMed Web of Science ®Google Scholar
• Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9(6):685-93
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
   PubMed Web of Science ®Google Scholar
• Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003;1(7):1356-70
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Fushida S, Bando E, Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 2001;37(7):918-23
   PubMed Web of Science ®Google Scholar
• Bruce D, Tan PH. Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look? Expert Opin Investig Drugs 2011;20(10):1413-34
   PubMed Web of Science ®Google Scholar
• Anderson JC, McFarland BC, Gladson CL. New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med 2008;10:e23
   Google Scholar
• Koch S, Tugues S, Li X, Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011;437(2):169-83
   PubMed Web of Science ®Google Scholar
• Nomura M, Yamagishi S, Harada S, Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995;270(47):28316-24
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170(5):1445-53
   PubMed Web of Science ®Google Scholar
• Karcher S, Steiner HH, Ahmadi R, Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006;118(9):2182-9
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473(7347):298-307
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005;7(4):452-64
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277(5322):55-60
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284(5422):1994-8
   PubMed Web of Science ®Google Scholar
• Zagzag D, Amirnovin R, Greco MA, Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 2000;80(6):837-49
   Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ, Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10(8):858-64
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M, A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11(1):69-82
   PubMed Web of Science ®Google Scholar
• Shen Q, Wang Y, Kokovay E, Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. Cell Stem Cell 2008;3(3):289-300
   PubMed Web of Science ®Google Scholar
• Charles NA, Holland EC, Gilbertson R, The brain tumor microenvironment. Glia 2011;59(8):1169-80
   PubMed Web of Science ®Google Scholar
• Yu SP, Yang XJ, Zhang B, Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells. Chin Med J (Engl) 2011;124(17):2599-604
   Google Scholar
• Cheng L, Wu Q, Guryanova OA, Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun 2011;406(4):643-8
   PubMed Web of Science ®Google Scholar
• Zhao Y, Dong J, Huang Q, Endothelial cell transdifferentiation of human glioma stem progenitor cells in vitro. Brain Res Bull 2010;82(5-6):308-12
   Google Scholar
• Wang R, Chadalavada K, Wilshire J, Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468(7325):829-33
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Pallini R, Biffoni M, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468(7325):824-8
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6(4):273-86
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Stark-Vance V. Bevacizumab. and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncology 2005;7:369
   Google Scholar
• Friedman HS, Prados MD, Wen PY, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740-5
   PubMed Web of Science ®Google Scholar
• Cloughesy T. FDA accelerated approval benefits glioblastoma. Lancet Oncol 2010;11(12):1120
   PubMed Web of Science ®Google Scholar
• Drappatz J, Lee EQ, Hammond S, Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012;107(1):133-8
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm S, Chamberlain MC, A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010;116(22):5297-305
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE II, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Desjardins A, Vredenburgh JJ, Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010;12(12):1300-10
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Lassen U, Hansen S, Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010;12(5):508-16
   PubMed Web of Science ®Google Scholar
• Desjardins A, Reardon DA, Coan A, Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012;118(5):1302-12
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Peters KB, Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 2012;107(1):155-64
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Peters KB, Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011;117(23):5351-8
   PubMed Web of Science ®Google Scholar
• Lai A, Tran A, Nghiemphu PL, Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29(2):142-8
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012;82(1):58-66
   PubMed Web of Science ®Google Scholar
• Gomez-Manzano C, Holash J, Fueyo J, VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 2008;10(6):940-5
   PubMed Web of Science ®Google Scholar
• de Groot JF, Lamborn KR, Chang SM, Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2011;29(19):2689-95
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, di Tomaso E, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28(17):2817-23
   PubMed Web of Science ®Google Scholar
• Ahluwalia MS. 2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies. Expert Rev Anticancer Ther 2011;11(2):161-3
   PubMedGoogle Scholar
• Batchelor T MP, Neyns B, The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a phase III randomized study [abstract OT-25]. Neuro Oncol 2010;12(suppl 4):iv69-78
   Google Scholar
• Chi AS, Gerstner ER, Eichler AF, Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. ASCO Meeting Abstr 2009;27(15S):e13010
   Google Scholar
• Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29(7):1338-53
   PubMed Web of Science ®Google Scholar
• Neyns B, Sadones J, Chaskis C, Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 2011;103(3):491-501
   PubMed Web of Science ®Google Scholar
• Reardon DA, Vredenburgh JJ, Coan A, Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol 2011;105(3):621-7
   PubMed Web of Science ®Google Scholar
• Reardon DA, Vredenburgh JJ, Desjardins A, Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011;101(1):57-66
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Schiff D, Anderson SK, NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study. ASCO Meeting Abstr 2011;29(15_suppl):2033
   Google Scholar
• Hainsworth JD, Ervin T, Friedman E, Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2010;116(15):3663-9
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60(8):2178-89
   PubMed Web of Science ®Google Scholar
• Reardon D FH, Yung WKA, Brada M, A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2004;22(14s):110s
   Google Scholar
• Frederick B, Gustafson D, Bianco C, ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys 2006;64(1):33-7
   Google Scholar
• Drappatz J, Norden AD, Wong ET, Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2010;78(1):85-90
   Google Scholar
• Spratlin J. Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 2011;13(2):97-102
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5):780-7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guessous F, Kofman A, XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010;13(2):112-21
   PubMed Web of Science ®Google Scholar
• Wen PY, Prados M, Schiff D, Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). ASCO Meeting Abstr 2010;28(15_suppl):2006
   Google Scholar
• Reardon DA, Cloughesy T, Rich J, Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol 2012;69(1):281-7
   Google Scholar
• Iwamoto FM, Lamborn KR, Robins HI, Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 2010;12(8):855-61
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-80
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Vogelbaum MA, Wen PY, End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009;27(18):2905-8
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70(10):779-87
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R, Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91(3):329-36
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-72
   PubMed Web of Science ®Google Scholar
• Sawlani RN, Raizer J, Horowitz SW, Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study. Radiology 2010;255(2):622-8
   Google Scholar
• Sorensen AG, Batchelor TT, Zhang WT, A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009;69(13):5296-300
   PubMed Web of Science ®Google Scholar
• Ellingson BM, Malkin MG, Rand SD, Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol 2011;102(1):95-103
   Google Scholar
• Barajas RF Jr, Chang JS, Segal MR, Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253(2):486-96
   PubMed Web of Science ®Google Scholar
• Chen W, Delaloye S, Silverman DH, Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25(30):4714-21
   Google Scholar
• Takano S, Mashiko R, Osuka S, Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity. Brain Tumor Pathol 2010;27(2):89-94
   Google Scholar
• Gerstner ER, Eichler AF, Plotkin SR, Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol 2011;103(2):325-32
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Eriksen JG, Broholm H, Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 2010;118(8):585-94
   PubMed Web of Science ®Google Scholar
• Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15(14):4589-99
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Christensen JG, Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007;104(43):17069-74
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95
   PubMed Web of Science ®Google Scholar
• Du R, Lu KV, Petritsch C, HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13(3):206-20
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5(11):610-20
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-95
   PubMed Web of Science ®Google Scholar
• Franco M, Paez-Ribes M, Cortez E, Use of a Mouse Model of Pancreatic Neuroendocrine Tumors to Find Pericyte Biomarkers of Resistance to Anti-angiogenic Therapy. Horm Metab Res 2011;43(12):884-9
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Kim J, Ozawa T, Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2(4):306-14
   PubMed Web of Science ®Google Scholar
• Takano S. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol 2012;29(2):73-86
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012;9(7):378-90
   Google Scholar
• Moreno Garcia V, Basu B, Molife LR, Kaye SB. Combining Antiangiogenics to Overcome Resistance: rationale and clinical experience. Clin Cancer Res 2012;18(14):3750-61
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Wen PY, Cloughesy T, Kuhn J, Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). ASCO Meeting Abstr 2009;27(15S):2006
   Google Scholar